Solasia Pharma K.K. reported consolidated earnings results for the nine months ended September 30, 2018. For the period, the company reported revenue of JPY 110 million compared to JPY 409 million a year ago. Operating loss was JPY 1,538 million compared to JPY 424 million a year ago. Loss before tax was JPY 1,549 million compared to JPY 430 million a year ago. Loss attributable to owners of parent was JPY 1,533 million compared to JPY 411 million a year ago. Basic and diluted loss per share was JPY 17.16 compared to JPY 5.11 a year ago. Purchase of property, plant and equipment was JPY 41 million. Purchase of intangible assets was JPY 136 million compared to JPY 377 million a year ago. Net cash used in operating activities amounted to JPY 1,849 million compared with JPY 522 million a year ago.

The company provided consolidated earnings guidance for the year ending December 31, 2018. For the year, the company expects net sales in the range of JPY 100 million to JPY 600 million, operating loss in the range of JPY 3,200 million to JPY 3,000 million, loss before tax in the range of JPY 3,200 million to JPY 3,000 million, loss in the range of JPY 3,200 million to JPY 3,000 million and loss attributable to owners of parent in the range of JPY 3,200 million to JPY 3,000 million and basic loss per share of JPY 35.80 to JPY 33.56.